L. Dreosti

发表

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Jianying Zhou, Erdem Goker, Jun Zhao, 2019, The Lancet.

Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.

P. Ruff, N. Colombo, G. Scambia, 2020, Gynecologic oncology.

Survival of patients with Kaposi's sarcoma in the South African antiretroviral treatment era: A retrospective cohort study.

M. Egger, J. Bohlius, L. Dreosti, 2017, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer

M. Cristofanilli, M. Clemons, M. Basik, 2016, Breast Cancer Research and Treatment.

Recommendations for the management of adult chronic myeloid leukaemia in South Africa.

P. Ruff, L. Dreosti, V. Louw, 2011, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

PATIENTS WITH METASTATIC COLORECTAL CANCER

L. Dreosti, A. McMaster, R. Mothilal, 2013 .

Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial

R. Advani, R. Gascoyne, L. Gordon, 2016 .

Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT).

M. Cristofanilli, M. Clemons, M. Basik, 2013 .

Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.

Sung-Bae Kim, M. Piccart, J. Baselga, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.

Qingyuan Zhang, Kunwei Shen, Masakazu Toi, 2015, The Lancet. Oncology.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kazuhiro Yoshida, A. Benson, Y. Bang, 2018, The Lancet.

Guidelines for the treatment of myelodysplastic syndromes (MDS) in South Africa.

P. Ruff, J. Mahlangu, E. Verburgh, 2011, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.

Sung-Bae Kim, E. Perez, R. Gelber, 2014, The Lancet. Oncology.

Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement

O. Khorshid, L. Dreosti, J. Zekri, 2015, Journal of multidisciplinary healthcare.

Ipilimumab in Pretreated Patients With Advanced Malignant Melanoma: Results of the South African Expanded-Access Program

B. Rapoport, L. Dreosti, J. P. Jordaan, 2016, Journal of global oncology.

Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen

S. Rajkumar, N. Callander, A. Stewart, 2016, Blood Cancer Journal.

A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer

L. Dreosti, A. McMaster, R. Mothilal, 2014, Chemotherapy research and practice.

Bone marrow necrosis following ALL-trans retinoic acid therapy for acute promyelocytic leukaemia.

L. Dreosti, Werner R. Bezwoda, K. Guntert, 1994, Leukemia and Lymphoma.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.

Sung-Bae Kim, E. Perez, R. Gelber, 2014, The Lancet. Oncology.